MX2024001654A - Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos. - Google Patents
Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos.Info
- Publication number
- MX2024001654A MX2024001654A MX2024001654A MX2024001654A MX2024001654A MX 2024001654 A MX2024001654 A MX 2024001654A MX 2024001654 A MX2024001654 A MX 2024001654A MX 2024001654 A MX2024001654 A MX 2024001654A MX 2024001654 A MX2024001654 A MX 2024001654A
- Authority
- MX
- Mexico
- Prior art keywords
- psychoactive
- disorders
- medicines
- neurological conditions
- treating psychiatric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163230237P | 2021-08-06 | 2021-08-06 | |
| US202163240113P | 2021-09-02 | 2021-09-02 | |
| US202163255706P | 2021-10-14 | 2021-10-14 | |
| US202263325757P | 2022-03-31 | 2022-03-31 | |
| US202263328343P | 2022-04-07 | 2022-04-07 | |
| PCT/US2022/074369 WO2023015154A1 (en) | 2021-08-06 | 2022-08-01 | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001654A true MX2024001654A (es) | 2024-06-28 |
Family
ID=85156410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001654A MX2024001654A (es) | 2021-08-06 | 2022-08-01 | Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos. |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US11707446B2 (https=) |
| EP (1) | EP4380588A4 (https=) |
| JP (1) | JP2024530007A (https=) |
| KR (1) | KR20240072133A (https=) |
| AU (1) | AU2022325135A1 (https=) |
| CA (1) | CA3227360A1 (https=) |
| IL (1) | IL310334A (https=) |
| MX (1) | MX2024001654A (https=) |
| TW (1) | TW202327571A (https=) |
| WO (1) | WO2023015154A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024254190A2 (en) * | 2023-06-06 | 2024-12-12 | Transcend Therapeutics, Inc. | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
| US12295937B2 (en) | 2021-08-06 | 2025-05-13 | Transcend Therapeutics, Inc. | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
| US12343326B2 (en) | 2021-08-06 | 2025-07-01 | Transcend Therapeutics, Inc. | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
| MX2024001654A (es) | 2021-08-06 | 2024-06-28 | Transcend Therapeutics Inc | Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos. |
| KR20240165982A (ko) * | 2022-03-31 | 2024-11-25 | 트랜센드 테라퓨틱스 인코퍼레이티드 | 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996039133A1 (en) * | 1995-06-06 | 1996-12-12 | Neurobiological Technologies, Inc. | Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones |
| US8575194B1 (en) | 2004-08-31 | 2013-11-05 | Jack William Schultz | Treatment methods of cognitive, emotional and mental ailments and disorders |
| US20120108510A1 (en) | 2010-05-20 | 2012-05-03 | Emory University | Methods of improving behavioral therapies |
| EP2931291B1 (en) | 2012-12-11 | 2021-10-20 | The McLean Hospital Corporation | Xenon treatment as an adjunct to psychotherapy for psychiatric disorders |
| WO2017151980A1 (en) | 2016-03-03 | 2017-09-08 | Segreti Louis M | Cannabis-based bioactive formulations and methods for use thereof |
| WO2021257500A1 (en) | 2020-06-17 | 2021-12-23 | Lobe Sciences Ltd. | Methods and compositions for treating mild traumatic brain injury, post-traumatic stress disorder and mild traumatic brain injury with post traumatic stress disorder |
| JP2024512796A (ja) * | 2021-04-01 | 2024-03-19 | テラン バイオサイエンシーズ インク． | サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物 |
| MX2024001654A (es) | 2021-08-06 | 2024-06-28 | Transcend Therapeutics Inc | Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos. |
| EP4426685A4 (en) * | 2021-11-05 | 2026-01-07 | Terran Biosciences Inc | Isotopic salts, crystalline forms, stereoisomers of methylone and ethylone and their methods of use |
-
2022
- 2022-08-01 MX MX2024001654A patent/MX2024001654A/es unknown
- 2022-08-01 IL IL310334A patent/IL310334A/en unknown
- 2022-08-01 JP JP2024506546A patent/JP2024530007A/ja active Pending
- 2022-08-01 AU AU2022325135A patent/AU2022325135A1/en active Pending
- 2022-08-01 CA CA3227360A patent/CA3227360A1/en active Pending
- 2022-08-01 WO PCT/US2022/074369 patent/WO2023015154A1/en not_active Ceased
- 2022-08-01 KR KR1020247007349A patent/KR20240072133A/ko active Pending
- 2022-08-01 EP EP22854040.7A patent/EP4380588A4/en active Pending
- 2022-08-05 TW TW111129588A patent/TW202327571A/zh unknown
- 2022-08-15 US US17/887,962 patent/US11707446B2/en active Active
-
2023
- 2023-06-28 US US18/215,547 patent/US12059402B2/en active Active
- 2023-11-02 US US18/386,337 patent/US11969407B2/en active Active
-
2024
- 2024-05-09 US US18/659,413 patent/US12233046B2/en active Active
-
2025
- 2025-01-16 US US19/024,616 patent/US20250255846A1/en active Pending
- 2025-12-04 US US19/409,215 patent/US20260083699A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240058301A1 (en) | 2024-02-22 |
| WO2023015154A1 (en) | 2023-02-09 |
| US20240293357A1 (en) | 2024-09-05 |
| EP4380588A1 (en) | 2024-06-12 |
| US11969407B2 (en) | 2024-04-30 |
| US20230054211A1 (en) | 2023-02-23 |
| TW202327571A (zh) | 2023-07-16 |
| US12059402B2 (en) | 2024-08-13 |
| US20250255846A1 (en) | 2025-08-14 |
| CA3227360A1 (en) | 2023-02-09 |
| KR20240072133A (ko) | 2024-05-23 |
| US11707446B2 (en) | 2023-07-25 |
| JP2024530007A (ja) | 2024-08-14 |
| US12233046B2 (en) | 2025-02-25 |
| IL310334A (en) | 2024-03-01 |
| EP4380588A4 (en) | 2025-10-08 |
| US20260083699A1 (en) | 2026-03-26 |
| US20230338333A1 (en) | 2023-10-26 |
| AU2022325135A1 (en) | 2024-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024001654A (es) | Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos. | |
| ZA202107444B (en) | Nlrp3 inflammasome inhibitors | |
| PH12021550166A1 (en) | Nlrp3 inflammasome inhibitors | |
| PH12020550341A1 (en) | Niraparib formulations | |
| PH12021550381A1 (en) | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | |
| MX2024012095A (es) | Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiátricos y neurológicos | |
| PH12020552111A1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| CL2020001020A1 (es) | Derivados de bencimidazol y sus usos. | |
| JOP20220235A1 (ar) | 3-فينوكسي أزيتيدين-1-يل بيرازينات مستبدلة لديها نشاط ناهض لـ gpr52 | |
| JOP20190183A1 (ar) | معدِلات مستقبلات الاستروجين | |
| MX2021007142A (es) | Compuestos organicos. | |
| EA202091604A1 (ru) | Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом | |
| JOP20200079A1 (ar) | مثبطات مستقبل عامل نمو البشرة | |
| PH12021550957A1 (en) | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS | |
| HN2001000218A (es) | Un efecto compuesto derivado de la triptamina y sus analogos | |
| CR20240353A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| CL2019003467A1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| GEP20247629B (en) | Alcohol derivatives as kv7 potassium channel openers | |
| WO2024254190A3 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| EP4009949A4 (en) | OLFACTORY DELIVERY OF THERAPEUTIC COMPOUNDS TO THE CENTRAL NERVOUS SYSTEM | |
| CL2024000893A1 (es) | Derivados de amina bicíclicos como moduladores de receptor gabaa alfa5 | |
| JOP20240175A1 (ar) | مركبات بيرازولو بيريميدين، وتركيبات تشتمل عليها واستخداماتها | |
| MX2021007562A (es) | Analogos de pentamidina y usos para estos. | |
| JOP20230210A1 (ar) | أشكال بلورية من (4s)-42-كلورو-4-إثيل-37-فلورو-53-مثوكسي-23، 5-ديوكسو-41-(ثلاثي فلورومثيل)-23h-6-آزا-3 (4، 1) بيريدينا-1 (1)- تريازولو-2 (1، 2)، 7 (1) ثنائي بنزيناهبتافان-47-كربوكساميد | |
| MX2025014366A (es) | Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiátricos y neurológicos |